drugset / Trial / NCT04928586

Immunosuppressant Combined With Pirfenidone in CTD-ILD

NCT04928586

Phase 4 Unknown 200 enrolled Qilu Hospital of Shandong University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A prospective cohort study was used to observe the efficacy and safety of different immunosuppressive agents with/wo pirfenidone on CTD-ILD patients in Qilu Hospital of Shandong University for 36 months.The main research endpoints are lung function, patient dyspnea score, 6-minute walking distance, imaging indicators, primary disease activity, adverse reactions, etc.

Timeline

Start
2019-08-16
Primary completion
2024-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirfenidone Small molecule